The effect of pre-COVID and post-COVID vaccination on long COVID: A systematic review and meta-analysis
- PMID: 39580033
- DOI: 10.1016/j.jinf.2024.106358
The effect of pre-COVID and post-COVID vaccination on long COVID: A systematic review and meta-analysis
Abstract
Background: Long COVID affects millions of people and results in a substantial decrease in quality of life. Previous primary studies and reviews attempted to study the effect of vaccination against long COVID, but these studies varied in the cut-off time of long COVID. We adhered to the WHO's definition of long COVID and conducted a systematic review and meta-analysis on the effect of pre-COVID and post-COVID vaccination on long COVID.
Methods: We obtained data from 13 databases up to 18 February 2024, including peer reviewed and preprint studies. Our inclusion criteria were: (1) long COVID definition as 3 months or beyond, (2) comparing long COVID symptoms between vaccinated and unvaccinated groups, (3) subjects received vaccinations either before or after infected with COVID, (4) the number of doses received by participants was specified. We extracted study characteristics and data and computed the summary odds ratio (OR) with the DerSimonian and Laird random effects model. We then performed subgroup analyses based on the main vaccine brand and long COVID assessment method. ROBINS-I framework was used for assessment of risk of bias and the GRADE approach was used for evaluating the certainty of evidence.
Findings: We included data from 25 observational studies (n = 14,128,260) with no randomised controlled trials. One-dose pre-COVID vaccination did not have an effect on long COVID (number of studies = 10, summary OR = 1.01, 95% CI = 0.88-1.15, p-value = 0.896). Two-dose pre-COVID vaccination was associated with a 24% reduced odds of long COVID (number of studies = 15, summary OR = 0.76, 95% CI = 0.65-0.89, p-value = 0.001) and 4 symptoms (fatigue, headache, loss of smell, muscle pain) out of 10 symptoms analysed. The OR of three-dose pre-COVID vaccination against overall long COVID was statistically insignificant but was far away from 1 (number of studies = 3, summary OR = 0.31, 95% CI = 0.05-1.84, p-value = 0.198). One-dose post-COVID vaccination was associated with a 15% reduced odds of long COVID (number of studies = 5, summary OR = 0.85, 95% CI = 0.73-0.98, p-value = 0.024). The OR of two-dose post-COVID vaccination against long COVID was statistically insignificant but was far away from 1 (number of studies = 3, summary OR = 0.63, 95% CI = 0.38-1.03, p-value = 0.066).
Interpretation: Our study suggests that 2-dose pre-COVID vaccination and 1-dose post-COVID vaccination are associated with a lower risk of long COVID. Since long COVID reduces quality of life substantially, vaccination could be a possible measure to maintain quality of life by partially protecting against long COVID.
Keywords: Long COVID; Meta-analysis; Odds ratio; Systematic review; Vaccination.
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Viral Variants, Vaccinations, and Long Covid - New Insights.N Engl J Med. 2024 Aug 8;391(6):561-562. doi: 10.1056/NEJMe2407575. Epub 2024 Jul 17. N Engl J Med. 2024. PMID: 39018529 No abstract available.
-
The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis.Clin Microbiol Infect. 2024 Dec;30(12):1505-1513. doi: 10.1016/j.cmi.2024.07.006. Epub 2024 Jul 14. Clin Microbiol Infect. 2024. PMID: 39002665
-
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1. Trials. 2021. PMID: 33849629 Free PMC article.
-
Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis.Lancet Child Adolesc Health. 2023 Jun;7(6):379-391. doi: 10.1016/S2352-4642(23)00078-0. Epub 2023 Apr 18. Lancet Child Adolesc Health. 2023. PMID: 37084750 Free PMC article.
-
SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.J Infect. 2023 Dec;87(6):506-515. doi: 10.1016/j.jinf.2023.08.009. Epub 2023 Sep 28. J Infect. 2023. PMID: 37777159
Cited by
-
Management of SARS-CoV-2 Infection-Clinical Practice Guidelines of the Polish Association of Epidemiologists and Infectiologists, for 2025.J Clin Med. 2025 Mar 27;14(7):2305. doi: 10.3390/jcm14072305. J Clin Med. 2025. PMID: 40217755 Free PMC article. Review.
-
Long COVID: A Systematic Review of Preventive Strategies.Infect Dis Rep. 2025 May 21;17(3):56. doi: 10.3390/idr17030056. Infect Dis Rep. 2025. PMID: 40407658 Free PMC article. Review.
-
Self-medication and off-label prescribing in post COVID-19 syndrome: Baseline data of a randomized acupressure and qigong trial.Integr Med Res. 2025 Sep;14(3):101197. doi: 10.1016/j.imr.2025.101197. Epub 2025 Jul 5. Integr Med Res. 2025. PMID: 40727709 Free PMC article.
-
COVID-19 Vaccination Timing, Relative to Acute COVID-19, and Subsequent Risk of Long COVID.medRxiv [Preprint]. 2025 Apr 23:2025.04.22.25326224. doi: 10.1101/2025.04.22.25326224. medRxiv. 2025. PMID: 40313290 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical